Botulinum toxin for sialorrhea
Klappenbach R, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32016001116
Spanish
Authors' recommendations:
Low-quality evidence shows that botulinum toxin, compared with placebo, might reduce sialorrhea at short term in patients refractory to initial hygienic-dietary and/or pharmacological treatment, and might have an efficacy similar to other pharmacological alternatives, with a lower incidence of mild adverse effects.
Regulatory agencies from Argentina, the United States and Europe approved the use of botulinum toxin but not for the treatment of sialorrhea (its use in this pathology is "off-label").
Most clinical practice guidelines consider the use of botulinum toxin as one of the therapeutic options for sialorrhea in patients refractory to initial treatment. The United States health insurers consulted cover botulinum toxin for those cases of sialorrhea refractory to initial treatment. The Latin American health systems consulted do not cover this technology for this indication.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Botulinum Toxins, Type A
- Sialorrhea
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.